SCHEMBL5733118

SCHEMBL5733118

C/C=C\c1cccc(C(=O)CP(=O)(OC)OC)c1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 2/20 0.44
▸ LMNA P02545 1/20 0.44
▸ P4HB P07237 3/20 0.39
▸ BCHE P06276 1/20 0.38
▸ HDAC3 O15379 1/20 0.38
▸ HDAC1 Q13547 1/20 0.38
▸ TTR P02766 2/20 0.37
▸ SNCA P37840 1/20 0.36
▸ RXFP1 Q9HBX9 2/20 0.36
▸ GRIN2D O15399 1/20 0.36
▸ GRIN3B O60391 1/20 0.36
▸ GRIN1 Q05586 1/20 0.36
▸ GRIN2A Q12879 1/20 0.36
▸ GRIN2B Q13224 1/20 0.36
▸ GRIN2C Q14957 1/20 0.36
▸ GRIN3A Q8TCU5 1/20 0.36
▸ ABCB1 P08183 2/20 0.35
▸ MAOB P27338 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5733123 1.00 POLB (0.44) POLBLMNAP4HBBCHEHDAC3
SCHEMBL5733122 0.80 RXFP1 (0.39) POLBLMNAP4HBBCHEHDAC3
SCHEMBL5732711 0.78 POLB (0.50) POLBLMNAP4HB
SCHEMBL11563059 0.77 TTR (0.43) POLBP4HBBCHEHDAC3HDAC1
SCHEMBL10682789 0.77 ERCC5 (0.50) POLBLMNA
SCHEMBL5732667 0.77 CES2 (0.57) POLBLMNAHDAC3HDAC1
SCHEMBL9547926 0.77 NPC1 (0.49) POLBLMNAHDAC1
SCHEMBL5733071 0.77 L3MBTL1 (0.49) POLBLMNARXFP1
SCHEMBL5732625 0.76 LMNA (0.38) POLBLMNAGRIN2DGRIN3BGRIN1
SCHEMBL5734221 0.75 LMNA (0.47) POLBLMNARXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1409455-B1 PROSTAGLANDIN ANALOGUES-AS EP4 RECEPTOR AGONISTS HOFFMANN LA ROCHE (CH) 2006-01-04 — — EP disclosed
US-6900336-B2 8-aza-11-deoxy prostaglandin analogues SYNTEX (U.S.A.) LLC (US) 2005-05-31 — — US disclosed
EP-1409455-A1 PROSTAGLANDIN ANALOGUES-AS EP4 RECEPTOR AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2004-04-21 — — EP disclosed
US-20030120079-A1 Such as 7-((R)-2-((E)-3-(3-Benzyl-phenyl)-3-hydroxy-propenyl)-5-oxo-pyrrolidin-1-yl)-heptanoic acid; side effects reduction SYNTEX (U.S.A.) LLC 2003-06-26 — — US disclosed
WO-2003008377-A1 PROSTAGLANDIN ANALOGUES_AS EP4 RECEPTOR AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2003-01-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030120079-A1 Such as 7-((R)-2-((E)-3-(3-Benzyl-phenyl)-3-hydroxy-propenyl)-5-oxo-pyrrolidin-1-yl)-heptanoic acid; side effects reduction PTGER4, FFAR4, PTGER1 POLB 3426/4885LMNA 3569/4885P4HB 1163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback